Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Generic Drugs

Generic Drugs

                        Overview & Basics
          Industry Resources
          Approvals & Reports
          Science & Research
          Patient Education Home
          Drugs
          Resources | Drugs
          Information for Consumers and Patients | Drugs
          Buying & Using Medicine Safely
          Generic Drugs
          Complex Generics NewsGeneric Drugs Complex Generics News
  
  					Up-to-date information on FDA’s actions on complex generics
	
    Share
    Post
    Linkedin

    Email
    PrintGenerally, complex generics are products that have complex active ingredients, formulations, dosage forms, or routes of administration, or are complex drug-device combination products. Generics of complex brand name drugs (i.e., reference listed drugs) can be more difficult to develop. As such, a complex drug may be less likely to have an available generic.

To help patients access important medical treatments, FDA’s Center for Drug Evaluation and Research works to better understand the scientific issues impacting complex generic development and assessment. FDA shares these scientific insights publicly, further enabling generic drug applicants to develop complex products and helping to ensure that applicants have the necessary information to prepare complete submissions.

This page features news, information, and additional resources about FDA’s activities that support the development and approval of complex generic drugs.

Approvals

Every year, FDA approves or tentatively approves hundreds of generic drug applications, including dozens of complex generics. Below is a list of recent notable complex generic approvals.

On July 6, 2023, FDA approved the first generic Vivitrol (naltrexone for extended-release injectable suspension), 380 mg/vial, single-dose vialEvents

Below is a list of recent and upcoming events regarding complex generics.

**Upcoming**

September 13-14, 2023: SBIA Workshop: Advancing Generic Drug Development: Translating Science to Approval 2023
	October 12, 2023: FDA/CRCG Workshop: Advances in PBPK Modeling and its Regulatory Utility for Oral Drug Product Development**Recent**

May 2, 2023: SBIA Webinar: Navigating the First ICH Generic Drug Draft Guideline “M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms”
	May 10, 2023: FDA/CRCG Training: Drug-Device Combination Products 101: Identifying, Developing, and Evaluating Drug-Device Combination Products
	May 11 – 12, 2023: Fiscal Year 2023 Generic Drug Science and Research Initiatives Public Workshop
	May 15, 2023: SBIA Webinar: A Deep Dive: GDUFA III Scientific Meetings
	June 15, 2023: FDA/CRCG Workshop: Mitigation Strategies for Nitrosamine Drug Substance Related Impurities: Quality and Bioequivalence Considerations for GenericsGuidances

Guidance documents represent FDA's current thinking on a topic and may discuss more specific products or issues that relate to the design, production, labeling, promotion, manufacturing, and testing of regulated products. Below is a list of recently publishedguidances and other documents related to complex generics.

Product-specific guidances (PSGs) provide recommendations for developing generic drugs and generating the evidence needed to support abbreviated new drug application (ANDA) approval, thereby helping to streamline generic drug product development by industry and ANDA assessment by FDA.

In May 2023, FDA published 47 draft PSGs, of which 25 were for complex products (14 new and 11 revised). FDA also updated the Upcoming Product-Specific Guidances for Generic Drug Product Development web page, which is updated each time FDA publishes a new batch of PSGs.
	In May 2023, FDA published an update to Manual of Policies and Procedures (MAPP) “Assessment of Bioequivalence Studies with Clinical Endpoints in ANDAs” (MAPP 5210.4 Rev. 3).
	In April 2023, FDA published two revised draft guidances related to the design and conduct of studies for evaluating transdermal and topical delivery systems (TDS) submitted abbreviated new drug applications (ANDAs):
	Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs
		Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAsResearch-related Articles

FDA’s GDUFA Science and Research Program provides new tools for FDA to evaluate generic drug equivalence and for industry to efficiently develop new generic products. Below are recent FDA articles focusing on complex generics.

Increasing Impact of Quantitative Methods and Modeling in Establishment of Bioequivalence and Characterization of Drug Delivery
	Establishing the Suitability of Model-Integrated Evidence to Demonstrate Bioequivalence for Long-Acting Injectable and Implantable Drug Products: Summary of Workshop
	Regulatory Utility of Mechanistic Modeling to Support Alternative Bioequivalence Approaches: A Workshop Overview
	Product Quality Research for Developing and Assessing Regulatory Submissions for Generic Cyclosporine Ophthalmic Emulsions
	Development of In Vitro-In Vivo Correlations for Long-Acting Injectable Suspensions. International Journal of Pharmaceutics
	The Role of Capsule Aperture Size on the Dispersion of Carrier-based Formulation at Different Air Flowrates
	Investigating Structural Attributes of Drug Encapsulated Microspheres with Quantitative X-ray Imaging
	Topical Pharmacokinetics of Brinzolamide Suspensions in Rabbits and Variability Analysis for Sample Size and Design ConsiderationsAdditional Resources

Further information on complex generics is available at the links below.

The Center for Research on Complex Generics
	Product-Specific Guidances for Generic Drug Development
	Upcoming Product-Specific Guidances for Generic Drug Product Development
	GDUFA Science and Research
	Generic Drug Research Priorities and Projects
	FDA Drug Competition Action Plan
	Infographic GDUFA III – Summary of T-Cons and Meetings (PDF - 117 KB)

                                                                                  Content current as of:
      08/22/2023
              
              
Regulated Product(s)
		 DrugsGeneric Drugs

          
                        Overview & Basics
          Industry Resources
          Approvals & Reports
          Science & Research
          Patient Education
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop